梅里埃新闻信息 梅里埃中国介绍 梅里埃全球介绍  

【生物医药】

生物梅里埃:应时而进 顺势而生

本报记者  吴红月

    3月26日,国家主席习近平和夫人彭丽媛在法国访问时专程来到生物梅里埃公司的产品展示厅,参观细菌学和感染性疾病的诊断成果,对此,生物梅里埃人感受到了莫大的喜悦。数据显示,在中国,生物梅里埃市场销售份额已经占到其全球市场的第三位,即将升为第二。6月12日,生物梅里埃副总裁、全球商业运营及投资顾问关系高级执行副总裁、大中华区负责人柏谦立先生在接受科技日报记者采访时表示,生物梅里埃将扩大在华业务,增加研发投入,倡导在体外诊断试剂和食品微生物检测领域引领创新,积极参与中国政府的医疗服务计划,实施“在中国,为中国”的核心发展目标,他说,“生物梅里埃要与中国共同发展”。

生产在中国 研发在中国

    一个如IPHONE5一样大小的检测试剂片,上面有几个凹进去小孔洞,每一个小孔代表了一种细菌,将检测液体点一滴在上面,立刻就会显现出有哪些细菌存在。“这个快速检测卡片叫做‘talking strip’,是刚刚在中国研发的,目前正在调试阶段,未来将在全球上市,其价格不过1欧元。”柏谦立说,这个产品的特点是价格低廉,操作简易,携带方便,非常适合基层边远地区的医疗卫生机构使用。
     生物梅里埃是法国最大的体外诊断公司、全球最大的微生物体外诊断公司,在临床微生物及工业应用微生物领域全球市场份额第一;在传染疾病诊断行业全球排行第三,尤其擅长艾滋病和肺结核的诊断;在免疫分析领域,其拳头产品VIDAS是当今世界上免疫分析实验室中安装实用数量居第二位的自动化免疫分析仪,在抗生素药敏检测领域,生物梅里埃也处于世界领先水平;是仅有的几家能够完全掌握分子生物学三步技术(提纯、扩增和检测)的公司之一。
     2013年,公司总营业额为15.88亿欧元,其中的12%投入研发。 “研发是生物梅里埃致胜的法宝。我们有超过1000名的研发人员,使公司的产品始终保持在业界先进水平” ,柏谦立先生说。随着经济的快速发展,中国市场已经成为生物梅里埃的主要战略重点之一,除法国和美国之外,中国的研发中心正在承担越来越重要的角色。“我们希望结合中国市场特色创新技术,生产便捷、快速、廉价的产品,‘生产在中国,创新在中国’,talking strip就是这一核心理念最好的体现。”他强调。

关注基层医疗机构检测市场

    从进入中国开始,生物梅里埃公司就非常重视对提升中国卫生事业给予支持和帮助。2005年,和中国医学科学院共同设立了联合实验室,旨在鉴别新兴病原体和防治新发传染性疾病;2006年,和复旦大学附属肿瘤医院联手,建立致力于发现肿瘤标记物的联合实验室,主要对乳腺癌和直肠癌进行研究;2008年,卫生部与生物梅里埃开展感染控制(HAI)项目,围绕耐药菌的诊断,涉及北京协和医院、中日友好医院等三甲医院;2010年,支持中南大学湘雅医学院建立“微生物检验专业人员培训基地”,在天津,国内首个检测“耐多药结核”示范实验室挂牌;2012年,常州市疾控中心从生物梅里埃引进细菌快速鉴定系统、生物质谱仪、细菌药敏分析系统、基因探针检测系统、微生物定量检测系统等9台检测仪器和一台中央处理系统,实现了微生物检测自动化和标准化。2013年,与西安交大一附院建立“微生物示范实验室”,这是在中国西部建立的首家微生物自动化示范实验室。
    今年年底,生物梅里埃还要在成都、武汉等地建立联合实验室,向中西部的基层卫生医疗机构提供更多的解决方案。
    柏谦立表示,他们在中国深入到基层的医疗机构做过广泛深入的调研,了解到这是一个具有很大的需求市场。他说,“在基层公共卫生机构,微生物试验检测平台可以更大程度上指导医生合理使用抗生素。对于医院来说,建立相应的实验室可以提供更全面更实时的细菌鉴定药敏数据和院内感染信息系统共享,有效地提升感染检测的实时性和响应度,为有效控制院内感染打下良好的基础。”

以历史和长远眼光看发展

    1978年,生物梅里埃公司总裁阿兰.梅里埃首次来华寻求合作,正值中国刚刚开始改革开放,他以历史性的眼光为中法卫生领域开辟了广阔的合作空间。
自上个世纪80年代以来,生物梅里埃公司先后在香港和上海、北京、广州、成都设立分公司。经过30多年的发展,自动化微生物鉴定分析系统的用户已达1400余家,自动微生物培养系统已达700余家,全自动细菌计数系统60余台,手工检测产品用户覆盖全国70%的省市。同时,生物梅里埃还建立基金和,支持新疆、广西等地区肺结核防治以及培养科研创新人才。
    为了表彰生物梅里埃公司对中国卫生事业发展做出的积极贡献,2011年6月,卫生部陈竺部长授予阿兰.梅里埃先生中国卫生合作的最高奖——“中国卫生奖”。
     今天,中国的医疗体制改革正在逐步深入,从基层着眼,完善公共卫生和医疗服务体系,特别是基层传染病防治能力建设已成为国家医疗卫生体制改革的重点工作之一。认识到中国的这一大趋势,柏谦立先生提出了“向西、向西、再向西”的发展方针,希望逐步将示范试验基地建设和对基层公共卫生人员的培训从沿海地区向西部延伸。
    柏谦立先生表示,外国企业在中国发展,要以谦虚的心态,历史的眼光和长远的发展为立足点,尊重中国的政策,顺应当地的市场规则。只有这样,才能顺利达成“在中国,为中国”的共同发展目标。
    中国传统文化中讲求“应时而进”、“顺势而生”,意即做事为人要顺应天时,结合地利,崇信人和,方能有所成就。而这也正是生物梅里埃公司在中国成功发展的真实写照。


BioMérieux: temporize, progress, and growth with the tide of the time.

Newspaper reporter: Wu Hongyue

On March 26, President Xi Jinping and his wife Peng Liyuan come to bioMérieux company’s showrooms to visit the diagnostic results of bacteriology and infectious diseases while they visited in France. For this, all staff of bioMérieux feel a great delight. Data show that bioMérieux’s market share in China has ranked the third among its global market business, and will soon climb to be the second. On June 12, Mr. Thierry Bernard, global vice president of bioMérieux, said that bioMérieux will expand its business in China, increase R&D investment, promote leading innovation in the field of IVD and food safety, and actively participate in the healthcare program by Chinese government, and implement the core objective of “In China, For China, With China", and he also said bioMérieux is always developing with China jointly, while he was interviewed by the reporter from Science and Technology Daily.

Production in China, R & D in China

A strip, whose size is same as IPHONE5, there are several small hollowed holes in it, and each represents a kind of bacteria. When you dropping the sample on the hole, the strip will immediately detect which type of bacteria are existing. This product is called “talking strip”, which is researched in China and currently in commissioning phase, will be available worldwide in the near future. And its price is only one euro” said Mr. Thierry Bernard, “the characteristics of the product is inexpensive, simple-to-use, portable, and very suitable for those primary healthcare institutions in remote areas”.

BioMérieux is the largest IVD company in France, the world's largest micro-organisms IVD company. And in the field of clinical microbiology and industrial application of microbial field, its global market share ranks the first; In infectious disease diagnostics industry, it ranks the third in the world, specializing in the diagnosis of AIDS and tuberculosis; In the immunoassay field, its leading product VIDAS is an automated immunoassay analyzer, and the amount of its setup utility ranks the second in the world's immunoassay laboratory. In the field of antibiotic susceptibility testing, bioMérieux is also in a world leading level; it is one of only a few companies which can perfect itself in the three-step molecular biology techniques (purification, amplification and detection).

In 2013, the company's total turnover amounted to 1.588 billion euros, of which 12% was invested in R&D. "R&D is the key to success of bioMérieux. We have more than 1,000 R&D personnel, who keep the company's product at the advanced level in the industry," Mr. Thierry Bernard said. With the rapid economic development, the Chinese market has become one of the main strategic focus of bioMérieux. In addition to France and the United States, Chinese R&D centers are taking on an increasingly important role. "We hope to product more convenient, rapid and cheap products combining with innovative technology of the Chinese market characteristics. “Production in China, Innovation in China”, talking stripe is the best embodies about the core philosophy." He stressed.

Attention on the market of primary healthcare institutions

Since entering into China, bioMérieux attaches a great importance to its support to enhance the healthcare in China. In 2005, bioMérieux and the Chinese Academy of Medical Sciences jointly set up a joint laboratory aiming at the identification of emerging pathogens and prevention of emerging infectious diseases; in 2006, bioMérieux and Shanghai Cancer Hospital of Fudan University jointly established a joint laboratory aiming at the discovery of tumor biomarkers and mainly for breast and colorectal cancer research; in 2008, the Ministry of Health and bioMérieux carried out HAI projects on the diagnosis of drug-resistant bacteria, involving in Beijing Union Medical College Hospital, China-Japan Friendship Hospital and other grade 3 and first-class hospitals; in 2010, bioMérieux support Xiangya School of Medicine of Central South University to establish a "training base for microbiological testing professionals ". In Tianjin, China's first demonstration laboratory for the detection of "MDR-TB" was established; in 2012, Changzhou CDC introduce bacteria rapid identification systems, bio-mass spectrometer, bacterial susceptibility analysis system, gene probe detection systems, microorganisms quantitative detection systems and other nine detection equipment and a central processing system from bioMérieux to achieve the microbiological testing automation and standardization. In 2013, bioMérieux and the First Affiliated Hospital of Xi'an Jiaotong University established "microbial demonstration laboratory", which is the first automated microbiological demonstration laboratory established in western China.

At the end of the year, bioMérieux will also establish joint laboratories in Chengdu, Wuhan and other places, to provide more solutions to those primary health care institutions in Midwest of China.
 
Mr. Thierry Bernard said that they have carried out an extensive research in those primary healthcare institutions in China, and learned that it is a great market demand. He said, "in the local primary healthcare institutions, microbiological assay platform can guide physicians a greater degree of rational use of antibiotics. For hospitals, the establishment of appropriate laboratory can provide more comprehensive and real-time bacterial identification and susceptibility data and share nosocomial infections information systems, and effectively improve the timeliness and responsiveness of infection detection, so as to lay a good foundation for the effective control of nosocomial infections."

Development with history and the long-term perspective

In 1978, Mr. Alain Mérieux, the president of bioMérieux, came to China for the first time to seek cooperation. That is just a time when China has just started reform and opening up. He opened up a broad space for Sino-French cooperation in health field.

Since the 1980s, bioMérieux has set up its branches in Hong Kong and Shanghai, Beijing, Guangzhou and Chengdu. After their development for 30 years, the amount of users of automated microbial identification and analysis system has reached more than 1400, automatic microbial culture system has reached more than 700 users, with more than 60 automatic bacteria counting systems, users for manual testing products has covered 70% of the provinces. Meanwhile, Fondation Mérieux has also been established to support the TB prevention and control in Xinjiang, Guangxi and other areas and also develop research and innovation talents.

In recognition of the positive contribution and devotion to Chinese healthcare development by bioMérieux, in June 2011, the Minister of Health Mr. Chen Zhu granted the highest Chinese health cooperation award -"Chinese Health Award" to Mr. Alain Mérieux.

Today, China’s health care reform is gradually deepening. Focusing on the primary health care institutions, improving public health and health care system, especially improving the skills of prevention and treatment for infectious diseases in the primary health care institutions has become one of the priorities of the national health system reform. Recognizing this developing trend of China, Mr. Thierry Bernard proposed the development guideline "west, west, then west", hoping gradually extending the demonstration laboratory base construction and training for public health workers in primary health care institutions from the coast to the west areas in China.

Mr. Thierry Bernard said that the development of foreign enterprises in China should take humility, with historical vision and long-term development as a standpoint, comply with China's policies and local rules of the market, which is the only way to successfully reach the common development goals "In China, For China, With China".

Chinese traditional culture stresses "progress by the time", "taking advantage of an opportunity for development", which means doing things and behaviors should adapt itself to conform to favorable climate, combined with favorable geographical location, and support from the people, then you can have success and achievements. And this is what a true portrayal of bioMérieux successful development in China.


生物梅里埃中国有限公司立足中国发展卫生事业

近日,生物梅里埃中国有限公司北京分公司迁址仪式在万豪写字楼举行。生物梅里埃公司创建于1963年,公司始终致力于开发作为医疗和工业用途的体外诊断产品。生物梅里埃的诊断系统是由试剂、仪器和软件组成,主要是为传染病、工业微生物控制、心血管病和肿瘤病等四个主要策略性领域来设计。梅里埃全球副总裁柏谦立先生介绍了生物梅里埃中国的使命:“生产在中国,创新在中国,服务全人类健康事业”的具体行动和目标,并分享了梅里埃在华的新动向。

bioMérieux China keep a foothold in China and develop health care

Recently, bioMérieux China held the opening ceremony of the relocation of bioMérieux Beijing Branch in Beijing Marriott Hotel. BioMérieux was established in 1963, it always devotes to develop IVD products to be used in medical field and industry. The diagnostic system of bioMérieux is composed of reagent, instrument and software, mainly designed for such four strategic fields as infectious diseases, industrial microorganism control, cardiovascular diseases, and tumor. Mr. Thierry Bernard, Global Vice-president of bioMerieux, introduced the mission of BioMérieux China “Production in China, Innovation in China, and service for public health” with its specific actions and objectives, and also shared the new development of bioMérieux in China.


企业网址:http://www.biomerieux.com.cn
电子邮件:hr-china@biomerieux.com

  生物梅里埃于上世纪80年代进入中国市场。1983年VITEK系统与美国麦道公司一起进入中国,1985年第一台VITEK仪器在卫生部北京医院落户,1987年与北京医院合作,成立培训中心和维修点,1987年第一次用户会在北京举行,1988年生物梅里埃公司从麦道手中收购了VITEK公司。随后第一台免疫酶标仪VIDAS和第一台半自动细菌鉴定仪ATB等相继在北京和上海落户。1997,98,99,2001年在北京、上海、成都和广州相继成立了办事处,以便生物梅里埃更好地为中国用户服务提供联络工作和售前与售后的技术支持等服务。生物梅里埃中国有限公司历经16年的发展,产品分布已达中国所有地区:全自动微生物分析系统VITEK的用户已达380余家,半自动细菌鉴定药敏仪ATB已达390余家,手工产品API细菌鉴定系列、性病系列及培养基市场占有率已达70%以上。

  生物梅里埃中国有限公司拥有多名微生物临床及工业领域专业人员和工程技术人员,其中许多人员都来自临床检验一线,拥有丰富的临床检验经验和仪器维修经验,全面负责生物梅里埃公司产品的销售,仪器的安装、维护及保养,以及用户的技术培训及技术支持。

   除了提供优质的产品和专业的服务外,生物梅里埃在中国一直致力于加强中国微生物界与海外的交流。因此,在中国差不多二十年的时间内,梅里埃请来很多国外的专家到国内讲课,其中较具代表性的包括美国NCCLS微生物组主席Dr. James Jorgensen,法国巴斯德研究所教授,人称“研究耐万古霉肠球菌之父”Prof. Pafrice Courvalin,美国华盛顿大学医学院教授,Dr. Daniel Sahm等。这些专家的讲课给我国微生物界带来了不少启迪。

   生物梅里埃公司16年前就将亚太地区作为公司发展的中坚力量,仅中国的业绩就以每年20%-30%的速度迅速增长。生物梅里埃通过优质高效的仪器和试剂、完善的售前售后服务和具有针对性的国内外技术交流为中国的微生物诊断领域提供了先进和行之有效的方法,因此树立了在该领域中领先与卓越的形象,引起了业内人士及国家领导人的关注。1998年初,朱鎔基总理会见了生物梅里埃公司主席阿兰梅里埃先生2002年7月阿兰 梅里埃先生在里昂总部接待上海市市长徐匡迪,就生物梅里埃公司进一步服务于中国市场进行了商讨。

生物梅里埃上海新基地

2011年3月,生物梅里埃宣布新基地落成。新基地坐落于上海浦东新区康桥,占地30亩地,是生物梅里埃公司继法国、美国之后、全球范围的第三大基地;新基地将成为梅里埃在亚太区是集生产、销售、培训和服务等功能为一身的职能中心。

   现时有约260名员工于上海生物梅里埃新基地上班。他们分别隶属于生产、销售、培训和服务等部门。更有法国总部驻华的员工,与我们一同不断完善各项生产、销售、服务等流程。

   新基地的落成将是梅里埃公司致力于中国卫生事业的新的里程碑!

企业网址:http://www.biomerieux.com.cn
电子邮件:hr-china@biomerieux.com

   生物梅里埃公司创建于1963年,公司依赖自身的科技研究和工业生产资源,始终致力于开发作为医疗和工业用途的体外诊断产品。 集团专门设计、开发、生产和推广应用在临床和工业的系统。生物梅里埃的诊断系统是由试剂、 仪器和软件组成,主要是为传染病、工业微生物控制、心血管病和肿瘤病等四个主要策略性领域来设计。

在2008年,公司销售额为11亿1千1百万欧元,集团共有11个生产基地和9个研究中心,分布于欧洲、北美洲和南美洲。集团全球拥有38个办事处,至2008年12月31日集团员工超过5,700人。

生物梅里埃公司产品有两个应用领域 : 临床和工业,临床市场占总销售额的85.5%,而工业市场占14.5%。工业的应用主要在食品、药品和化妆品的微生物分析,增长非常迅速,生物梅里埃是全球体外诊断领域的第八大生产商。

生物梅里埃中国有限公司已经20年的发展,自动化微生物鉴定分析系统的用户已达1400余家,自动微生物培养系统已达700余家,全自动细菌计数系统60余台,手工产品用户覆盖全国的省市70%以上。同时公司拥有数十名微生物临床及工业领域专业人员和工程技术人员,其中许多人员都来自检验一线,拥有丰富的检验经验和仪器维修经验。全面负责生物梅里埃公司产品的销售,仪器的安装、维护及保养,以及用户的培训及技术支持。

我们为员工提供具有竞争力的福利待遇和培训机会。应聘者请将中英文简历和近照发至我司邮箱,注明应聘职位。

电子邮件:hr-china@biomerieux.com

bioMérieux by Alain Mérieux
BioMérieux’s mission is to contribute to the improvement of public health worldwide through in vitro diagnostics. Throughout its history, our company has committed to four priorities, which today, represent its strength:
Our independence and expertise in the field of in vitro diagnostics allow us to respond rapidly in today’s complex environment and to form partnerships that are vital to our scientific and international growth.
Our international scope, with 84% of sales coming from outside of France. Established in 150 countries, with 39 subsidiaries and an extensive network of distributors, we are close to our customers, wherever they may be, and provide a line of products tailored to the realities of each region.
45 years of experience and know-how in the field of infectious diseases allows bioMérieux, a world leader in microbiology, to respond to major public health issues, and affirm its position as a key player in clinical diagnostics and industrial microbiological quality control.
Scientific and technological innovation is at the heart of the bioMérieux strategy. It has enabled us to extend our expertise to the fields of cancer and cardiovascular diseases, complementing that of infectious diseases. bioMérieux dedicates considerable resources to R&D (over 12% of its sales), pursuing an ambitious policy based on multidisciplinary internal teams and a network of international partnerships and scientific affiliations.
bioMérieux is part of the Mérieux Alliance group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.

Our Strategy
A strategy putting patients first
Our strategy is focused on pathologies and meeting the needs of clinicians, patients and consumers. We concentrate on infectious diseases - in particular, sepsis, hospital-acquired infections, tuberculosis, AIDS, and hepatitis - as well as on tests delivering high medical value for cancers (breast, colon, prostate) and emergency cardiovascular diseases.
In applications for the agri-food, pharmaceutical and cosmetic industries, bioMérieux aspires to be the undisputed leader.

Corporate Social Responsibility
As a corporate citizen, bioMérieux has made a long-term commitment to the following actions:
Improving access to diagnostics through our Public Health Department, focused on HIV/AIDS and tuberculosis.
Supporting public health initiatives in limited-resource countries through the Mérieux foundations and our constant commitment to the programs of major international organizations.
Upholding the Global Compact’s Principles: Since 2003, bioMérieux has been a member of the Global Compact, an international initiative under the auspices of the United Nations that aims to address the problems generated by globalization.
Being active in the local communities of our sites and subsidiaries, supporting charitable and cultural initiatives.


企业网址:http://www.biomerieux.com.cn
电子邮件:hr-china@biomerieux.com

1. 梅里埃诊断产品(上海)有限公司
中国上海市浦东新区康桥工业区浦三路4633号
邮编:201315
电话:(86-21) 6097 8388
传真:(86-21) 6097 8399
用电邮联络,请看以下项目

2. 生物梅里埃香港办事处
中国香港九龙长沙湾长裕街8号亿京广场19楼
电话:(852) 2356 7033
传真:(852) 2330 2085
用电邮联络,请看以下项目

3. 生物梅里埃北京办事处
北京市东城区建国门南大街7号万豪写字楼D座601&602&606C
邮编:100005
电话: (86-10) 8535 8388
传真: (86-10) 8535 8333
用电邮联络,请看以下项目
4. 生物梅里埃华南及西南办事处 (广州办事处)
中国广州市珠江新城珠江东路11号高德置地广场F座1402-04室
邮政编码:510623
电话:(86-20)87627010
传真:(86-20)87627015
用电邮联络,请看以下项目

5.生物梅里埃华南及西南办事处 (成都办事处)
中国成都市人民南路一段86号城市之心大厦16楼A、N单元
邮政编码:610016
电话:(86-28)-8620 2052
传真:(86-28) 8620 2051
用电邮联络,请看以下项目

6.香港商生物梅里埃有限公司台灣分公司
台北市信义区松山路130號8楼
电话: (886-2)2528 5180
传真: (886-2)2528 5233
用电邮联络,请看以下项目







未经51job.com同意,不得转载本网站之所有招聘信息及作品;无忧工作网版权所有©1999-